These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 2446744)

  • 21. Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors.
    Nakamura S; Nakata K; Kashimoto S; Yoshida H; Yamada M
    Jpn J Cancer Res; 1986 Aug; 77(8):767-73. PubMed ID: 3093425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy with adriamycin and interleukin 2 augments immunity against murine renal cell carcinoma.
    Gautam SC; Chikkala NF; Ganapathi R; Hamilton TA
    Cancer Res; 1991 Nov; 51(22):6133-7. PubMed ID: 1682042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
    J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
    Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J
    Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J; Hu P; Khawli LA; Epstein AL
    Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
    Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
    Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice.
    Nakamura S; Kashimoto S; Kajikawa F; Nakata K
    Cancer Res; 1991 Jan; 51(1):215-21. PubMed ID: 1899039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
    J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells.
    Wu B; Shen RN; Wang WX; Broxmeyer HE; Lu L
    Stem Cells; 1993 Sep; 11(5):412-21. PubMed ID: 8241952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
    Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
    Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The therapeutic activity in cancer of IL-2 in combination with other cytokines.
    Truitt GA; Brunda MJ; Levitt D; Anderson TD; Sherman MI
    Cancer Surv; 1989; 8(4):875-89. PubMed ID: 2701733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment regimen and host T-cell-dependent therapeutic effect of interferon in mouse solid tumors.
    Kataoka T; Matsuura N; Oh-hashi F; Suhara Y
    Cancer Res; 1985 Aug; 45(8):3548-53. PubMed ID: 2410097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
    Vallera DA; Taylor PA; Aukerman SL; Blazar BR
    Cancer Res; 1993 Sep; 53(18):4273-80. PubMed ID: 8364923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of recombinant murine interferon-gamma on the hematopoietic and immunological parameters of mice bearing metastatic Lewis lung carcinoma tumors.
    Young MR; Young ME; Wepsic HT
    Exp Hematol; 1988 May; 16(4):295-301. PubMed ID: 2966070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.